Study
| Multicenter, single-arm, phase II trial |
| Localized high-grade UTUC or radiographically visible invasive disease |
| Four cycles of split-dose GC (n=57) |
Efficacy
| Pathologic response rate: 63% (37 of 57 pts) |
| Complete response rate: 19% (11 of 57 pts) |
| 2-year PFS: 89% [81-98], 5-year PFS: 72% [59-87] |
| 2-year OS: 93% [86-100], 5-year OS: 79% [67-94] |
Safety
| Grade 3 AEs: Neutropenia (33%), febrile neutropenia (7.0%), thrombocytopenia (7.0%), creatinine increased (5.3%) |
J Clin Oncol 2023: 05 JAN
http://doi.org/10.1200/JCO.22.00763
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
